• Propanc Biopharma published preclinical results showing PRP restored chemotherapy vulnerability in resistant pancreatic cancer cells.
• PRP reduced cancer cell growth and invasive behavior, supporting its potential as a resistance-modulating treatment rather than conventional chemotherapy.
• A first-in-human Phase 1b trial is planned for Q1 2027 in Australia, targeting up to 50 patients with advanced solid tumors.
• The findings support potential sequential or combination use with RAS inhibitors; PRP holds FDA orphan drug designation for pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260830PRIMZONEFULLFEED9851919) on October 26, 2026, and is solely responsible for the information contained therein.